AMEA
Covers 498 genes and includes TMB, MSI-status, and
PD-L1 assessment.1
MSI, microsatellite instability; PD-L1, programmed death-ligand 1;
TMB, tumor mutation burden.
*Includes TERT promoter region.¹
†This test can be ordered at the same time as Guardant360 TissueNext. PD-L1 assessment from Guardant Galaxy uses AI-powered image analysis developed by Lunit®.
Important note: Guardant360 TissueNext and Guardant Galaxy PD-L1 were developed as Laboratory Developed Tests (LDTs), and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These tests have not been cleared or approved by the US FDA.